Postpartum hemorrhage (PPH) is defined as cumulative blood loss ≥1000 mL or blood loss with signs/symptoms of hypovolemia, irrespective of delivery route. [1-2] It is the leading cause of maternal mortality worldwide, accounting for ~27% of all maternal deaths. [3] PPH is classified as primary (within 24 hours of delivery) or secondary (24 hours to 12 weeks postpartum). [1-2] The causes are summarized by the "4 Ts": Tone (uterine atony, ~70%), Trauma (lacerations, ~20%), Tissue (retained placenta, ~10%), and Thrombin (coagulopathy, <1%). [1][4]
The following staged management algorithm illustrates the escalation framework from prevention through surgical intervention:
1. History
- Delivery details: Mode of delivery (vaginal vs. cesarean), operative vaginal delivery (forceps/vacuum), episiotomy, duration of labor (prolonged vs. precipitous), labor induction/augmentation [1][3]
- Third stage management: Was oxytocin given prophylactically? Was the placenta delivered intact? Manual extraction required? [4]
- Quantification of blood loss: Estimated volume, rate of bleeding (brisk vs. slow trickle), number of saturated pads, clots passed [1-2]
- Timing: Onset relative to delivery — within minutes (atony, trauma) vs. hours to weeks (retained products, infection, AVM) [2]
- Pregnancy complications: Preeclampsia, chorioamnionitis, placenta previa, abruption, polyhydramnios, multiple gestation [1]
- Prior obstetric history: Previous PPH (strong risk factor), prior cesarean sections, history of retained placenta [3]
- Bleeding history: Personal or family history of bleeding disorders (von Willebrand disease, hemophilia), easy bruising, menorrhagia [2]
- Medications: Anticoagulants, antidepressants (weak association), magnesium sulfate use [1][3]
2. Alarm Features
- Hemodynamic instability: Tachycardia (HR >100 bpm or increase ≥20 bpm from baseline), hypotension (SBP <90 mmHg), shock index ≥1.0 [6-7]
- Massive blood loss: Estimated blood loss >1500 mL — note that vital signs may remain normal until >25% of blood volume is lost (~1500 mL in late pregnancy) [1][4]
- Signs of DIC: Oozing from IV sites, petechiae, non-clotting blood, critically low fibrinogen (especially with abruption or amniotic fluid embolism) [4]
- Boggy, non-contracting uterus despite uterotonics [4]
- Uterine inversion (palpable fundal mass at introitus, severe pain, vasovagal response) [4]
- Expanding hematoma (vulvar, vaginal, or retroperitoneal) [4]
- Altered mental status, pallor, air hunger, oliguria [4]
- Failure to respond to first-line uterotonics — triggers escalation to tamponade, surgical intervention, or massive transfusion protocol [4]
3. Medications
Uterotonic agents (first-line for atony): [1][4]
Tranexamic acid (TXA): 1 g IV within 3 hours of birth — reduces bleeding-related mortality by up to 30% with no increase in adverse events. [2][9] Repeat dose of 1 g if bleeding continues after 30 minutes. [8]
Contraindicated medications: Methylergonovine in hypertensive disorders; carboprost in asthma. [1][4]
4. Diet
- Not directly applicable in the acute setting
- Post-recovery: Iron-rich diet (red meat, leafy greens, legumes) and oral iron supplementation for anemia correction
- Adequate hydration and caloric intake to support lactation and recovery
- Prenatal correction of anemia is a modifiable risk factor — anemia has a strong association with PPH [3]
5. Review of Systems
- Cardiovascular: Lightheadedness, palpitations, chest pain, syncope
- Neurologic: Altered mental status, visual changes (consider preeclampsia/eclampsia)
- GI: Nausea/vomiting (hypovolemia), diarrhea (medication side effect)
- GU: Decreased urine output (hypovolemia marker), urinary retention (can worsen atony)
- Infectious: Fever, chills, foul-smelling lochia (endometritis — especially in secondary PPH) [2]
- Hematologic: Easy bruising, bleeding from other sites (coagulopathy)
6. Collateral History and Family History
- Family history of bleeding disorders: Von Willebrand disease, hemophilia A/B, platelet disorders — important in secondary PPH [2]
- Prior obstetric history from partner or family: Previous PPH, retained placenta, cesarean deliveries
- Social context: Access to prenatal care (no antenatal care is a strong risk factor), substance use, support system for postpartum recovery [3]
- Collateral from delivering provider: Details of delivery, estimated blood loss, placental integrity, medications administered
7. Risk Factors
Strong association: [3]
- Previous PPH, cesarean birth, anaemia
- Multiple pregnancy, placenta previa, macrosomia (>4500 g)
- Female genital mutilation, sepsis, no antenatal care
- Assisted reproductive technology, shoulder dystocia
Moderate association: [3]
- BMI ≥30, gestational diabetes, polyhydramnios
- Preeclampsia, antepartum hemorrhage, COVID-19 infection
Weak association: [3]
- Black and Asian ethnicity, BMI 25–29.9
- Uterine fibroids, asthma, thrombocytopenia
- Antidepressant use, induction of labor, instrumental delivery, premature rupture of membranes
Delivery-specific: [1]
- Prolonged labor, precipitous delivery, chorioamnionitis
- Magnesium sulfate use, labor augmentation with oxytocin
- Operative vaginal delivery, episiotomy
Critically, PPH often occurs in women with no identifiable risk factors, mandating vigilance after all deliveries. [1]
8. Differential Diagnosis
Use the "4 Ts" framework: [1][4]
- Tone — Uterine atony (~70%): Boggy, poorly contracted uterus. Most common cause [3]
- Trauma — Genital tract injury (~10–20%): Cervical/vaginal/perineal lacerations, expanding hematomas, uterine rupture [1-2]
- Tissue — Retained products (~10–15%): Incomplete placental delivery, placenta accreta spectrum [1-2]
- Thrombin — Coagulopathy (<5%): DIC (from abruption, amniotic fluid embolism, severe preeclampsia), inherited disorders [2][4]
- Uterine inversion: Rare but life-threatening; fundus palpable at or through cervix [4]
- Uterine AVM/pseudoaneurysm: Rare; consider in secondary PPH with pulsatile bleeding [2]
Cannot-miss diagnoses: Amniotic fluid embolism (sudden cardiovascular collapse + DIC), uterine rupture (especially after prior cesarean), concealed retroperitoneal hemorrhage [1][4]
Secondary PPH differential: [2]
- Retained products of conception
- Endometritis
- Subinvolution of placental site
- Inherited coagulopathy (von Willebrand disease)
- Uterine AVM
9. Past Medical History
- Previous PPH — strongest predictor of recurrence [3]
- Prior cesarean sections (risk of placenta accreta spectrum) [1]
- Uterine surgery (myomectomy, D&C)
- Bleeding disorders or abnormal coagulation history
- Chronic hypertension, preeclampsia in prior pregnancies
- Uterine fibroids [3]
- Liver disease (impaired coagulation factor synthesis)
10. Physical Exam
Vital signs: [7]
- Heart rate, blood pressure, respiratory rate, SpO2
- Shock index (HR/SBP): Normal postpartum 0.52–0.89; ≥1.0 suggests significant hemorrhage [6-7]
Focused exam: [4]
- Uterine palpation: Fundal height, tone — a soft, boggy uterus = atony
- Bimanual exam: Assess lower uterine segment tone, clots, retained tissue
- Speculum exam: Systematic inspection of cervix, vaginal walls, and perineum for lacerations or expanding hematomas
- Placental inspection: Confirm completeness of membranes and cotyledons
- Bladder: Ensure emptied (distended bladder impairs uterine contraction)
- Skin: Pallor, diaphoresis, petechiae (DIC), capillary refill
11. Lab Studies
Initial labs: [1-2]
- CBC (hemoglobin/hematocrit — note: acute changes will not accurately reflect blood loss)
- Coagulation panel: PT/INR, aPTT
- Fibrinogen — critically important; low fibrinogen (<200 mg/dL) predicts severity and is especially concerning with abruption or amniotic fluid embolism [1][4]
- Type and crossmatch — reserve blood for transfusion
- Comprehensive metabolic panel
- Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) — point-of-care assessment of real-time clot formation to guide blood product selection [1-2]
Transfusion targets: [1]
- Hemoglobin >8 g/dL
- Fibrinogen >200 mg/dL (>2 g/L)
- Platelets >50,000/μL
- PT/aPTT <1.5× normal
12. Imaging
- Bedside ultrasound (first-line): Assess uterine contents — endometrial stripe >2 cm is highly suggestive of retained products of conception [2]
- FAST exam: Evaluate for intraperitoneal free fluid (hemoperitoneum after cesarean or uterine rupture) [2]
- Transvaginal ultrasound: Preferred for secondary PPH — identifies retained products, subinvolution, AVMs, pseudoaneurysms [2]
- CT angiography: For suspected uterine AVM or pseudoaneurysm when embolization is being considered
- Imaging is unnecessary when the cause is clinically obvious (e.g., clear uterine atony responding to uterotonics, visible laceration)
13. Special Tests
- Shock Index (SI): HR ÷ SBP; ≥1.0 associated with increased risk of massive transfusion [6]
- Quantitative blood loss (QBL): Calibrated drapes, gravimetric weighing of blood-soaked materials [1]
- Calibrated drape + clinical observations: Blood loss ≥300 mL with any abnormal vital sign, or ≥500 mL regardless, triggers PPH treatment [7][10]
- Tamponade test: Intrauterine balloon inflation — if bleeding stops, confirms uterine source; if not, surgical cause likely [9]
- Thromboelastography (TEG): Point-of-care viscoelastic testing for real-time coagulation assessment [2]
14. ECG
- Indications: Hemodynamic instability, chest pain, suspected amniotic fluid embolism, massive transfusion
- Findings to watch for: Sinus tachycardia (most common), ST changes (myocardial ischemia from hypovolemia), right heart strain pattern (amniotic fluid embolism), electrolyte-related changes (hyperkalemia from massive transfusion)
- Not routinely indicated in uncomplicated PPH
15. Assessment
Severity stratification: [1]
- PPH: Blood loss ≥1000 mL or signs of hypovolemia
- Severe PPH: Blood loss ≥1500 mL, hemodynamic instability, need for transfusion
- Massive hemorrhage: ≥10 units pRBCs in 24 hours or ≥4 units in 1 hour
Key clinical pearls
- Multiple concurrent causes occur in ~8% of cases — always reassess after treating the initial cause [3]
- Blood loss is routinely underestimated by visual estimation [1]
- The MOTIVE bundle (Massage, Oxytocic drugs, Tranexamic acid, IntraVenous fluids, Examination/Escalation) provides a systematic first-response framework [11]
16. Treatment Plan
Initial stabilization: [1-2][8]
- Call for help — activate PPH protocol/team
- Two large-bore IVs, isotonic crystalloid resuscitation (preferred over colloids) [8]
- Empty bladder (Foley catheter)
- Quantify blood loss (calibrated drape or gravimetric)
Stepwise management for uterine atony: [1][4]
- Bimanual uterine massage + remove intrauterine clots
- Oxytocin IV infusion (first-line uterotonic)
- TXA 1 g IV within 3 hours of delivery [2]
- Second-line uterotonics in rapid succession if no response: methylergonovine, carboprost, misoprostol
- Intrauterine balloon tamponade (controls >80% of cases refractory to uterotonics) [9]
- Uterine compression sutures (B-Lynch) if tamponade fails [1]
- Uterine artery embolization (if interventional radiology available) [8]
- Hysterectomy — definitive, life-saving intervention for refractory hemorrhage [4]
Transfusion: [1][4]
- Initiate when blood loss >1500 mL or hemodynamic instability
- Massive transfusion protocol: pRBCs:FFP:platelets in 1:1:1 ratio
- Add cryoprecipitate if fibrinogen <200 mg/dL
- Consider TEG/ROTEM-guided transfusion
For retained products: Manual extraction or suction curettage [2]
For lacerations: Systematic repair under adequate exposure [4]
For secondary PPH: Transvaginal ultrasound → suction curettage for retained products; IV antibiotics for endometritis; uterine artery embolization for AVMs [2]
17. Disposition
Admission criteria: [2][12]
- Any PPH requiring uterotonics beyond prophylactic oxytocin
- Blood transfusion required
- Hemodynamic instability at any point
- Surgical intervention (tamponade, compression sutures, hysterectomy)
- ICU admission: Massive transfusion, DIC, multiorgan dysfunction, hemodynamic instability despite resuscitation
Severe maternal morbidity triggers for chart review: [12]
- Transfusion of ≥4 units pRBCs
- Unplanned ICU admission
- Unplanned return to OR
- Unplanned hysterectomy
Transfer criteria: Patients at facilities without OB, anesthesia, hematology, or blood banking capabilities should be promptly transferred if bleeding does not resolve with standard interventions [2]
18. Follow-Up / Return Precautions
Follow-up
- Postpartum visit within 1–2 weeks for hemoglobin check and wound assessment
- Iron supplementation for anemia (oral ferrous sulfate 325 mg BID–TID; consider IV iron for severe anemia)
- Screen for inherited bleeding disorders if PPH was unexplained or secondary PPH occurred [2]
- Mental health screening — PPH is associated with postpartum PTSD, anxiety, and depression
- Contraceptive counseling and future pregnancy planning (discuss recurrence risk)
Return precautions — counsel patients to return immediately for:
- Heavy vaginal bleeding (soaking >1 pad per hour)
- Passage of large clots
- Lightheadedness, dizziness, or fainting
- Fever >38°C (100.4°F) or foul-smelling vaginal discharge (endometritis)
- Chest pain or shortness of breath
Expected recovery: Lochia should progressively decrease over 4–6 weeks. Secondary PPH can occur up to 12 weeks postpartum, most commonly from retained products or endometritis. [2]
References
1. Postpartum Hemorrhage. — Bienstock JL, Eke AC, Hueppchen NA. The New England Journal of Medicine. 2021.
2. Postpartum Hemorrhage. — Harvey SA. The Journal of the American Medical Association. 2025.
3. Causes of and Risk Factors for Postpartum Haemorrhage: A Systematic Review and Meta-Analysis. — Yunas I, Islam MA, Sindhu KN, et al. Lancet. 2025.
4. Practice Bulletin No. 183: Postpartum Hemorrhage. — Committee on Practice Bulletins—Obstetrics Obstetrics and Gynecology. 2017.
5. Hypovolemic Shock. — Jerasimos Ballas, Scott Roberts Critical Care Obstetrics, 7th Edition. 2024.
6. Delta Neutrophil Index and Shock Index Can Stratify Risk for the Requirement for Massive Transfusion in Patients With Primary Postpartum Hemorrhage in the Emergency Department. — Kong T, Lee HS, Jeon SY, et al. PloS One. 2021.
7. Tests for Diagnosis of Postpartum Haemorrhage at Vaginal Birth. — Yunas I, Gallos ID, Devall AJ, et al. The Cochrane Database of Systematic Reviews. 2025.
8. Implementation Strategies for WHO Guidelines to Prevent, Detect, and Treat Postpartum Hemorrhage. — Semrau K, Litman E, Molina RL, et al. The Cochrane Database of Systematic Reviews. 2025.
9. Management of Postpartum Hemorrhage: Recommendations From FIGO. — Hwang DS, Myers L. American Family Physician. 2023.
10. Prognostic Accuracy of Clinical Markers of Postpartum Bleeding in Predicting Maternal Mortality or Severe Morbidity: A WHO Individual Participant Data Meta-Analysis. — Gallos I, Williams CR, Price MJ, et al. Lancet. 2025.
11. Effects of Combinations of Diagnostic and Treatment Strategies for Postpartum Haemorrhage: A Network Meta-Analysis. — Yunas I, Price MJ, Vigneswaran K, et al. The Cochrane Database of Systematic Reviews. 2025.
12. Measurement and Improvement Strategies for Reduction of Severe Maternal Morbidity. — American College of Obstetricians & Gynecologists' Quality and Safety Initiatives Delegation Obstetrics and Gynecology. 2026.